|

Serum Endogenous Estrogens, Estrogen Receptors, and Sirtuin-1 and -3 After Resveratrol Supplementation

RECRUITINGN/ASponsored by InCor Heart Institute
Actively Recruiting
PhaseN/A
SponsorInCor Heart Institute
Started2026-08-24
Est. completion2029-08-24
Eligibility
Age45 Years – 70 Years
SexFEMALE
Healthy vol.Accepted

Summary

Atherosclerotic coronary artery disease (CAD) is a leading cause of mortality among postmenopausal women. Resveratrol, a phenolic compound with antioxidant properties, may influence lipid metabolism, endothelial function, and platelet aggregation, while sirtuin-1 and sirtuin-3 regulate metabolic and hormonal responses to nutritional stimuli. This randomized, double-blind, placebo-controlled trial evaluates the effects of trans-resveratrol supplementation (1000 mg/day) versus placebo, over 90 days, on serum estradiol and estrone levels, gene expression of estrogen receptors alpha and beta, and sirtuins 1 and 3 in 80 postmenopausal women with CAD. Findings may inform therapeutic strategies for postmenopausal women with chronic coronary disease.

Eligibility

Age: 45 Years – 70 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Postmenopausal women;
* Diagnosed coronary artery disease;
* Stable coronary disease;

Exclusion Criteria:

* Hypo- or hyperthyroidism,
* Rheumatic disease,
* Use of alcohol,
* hepatic failure,
* renal failure
* hormone replacement therapy
* use of insulin

Conditions4

Coronary Artery Disease (CAD)Heart DiseaseHormonesMenopause

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.